Clinico Radiological Series: Imaging of Chest Tumors Randeep Guleria, Ashu Seith Bhalla, Manisha Jana, Priyanka Naranje, Anant Mohan
INDEX
Page numbers followed by b refer to box, f refer to figure, fc refer to flowchart, and t refer to table.
A
Abdomen 411
Ablation 362
methods 364t
Acquired immunodeficiency syndrome 317
Acute respiratory distress syndrome 281, 367, 389
Adenocarcinoma 37, 38, 39f, 49, 51f, 53, 56f, 104f, 109f, 119121, 289, 300, 319f, 322, 334, 431f, 432f
biopsy suggestive of 319f
forms of 50
in situ 38, 50
invasive 39, 50
mucinous 40f, 312f, 435f
lepidic predominant 50
markers 41
micropapillary 54f
minimally invasive 39, 50
mucinous 52f, 53t
nonmucinous 53t, 105f
peripheral 47f
right hilar 387f
Adenoma, pleomorphic 120
Adrenocorticotropic hormone 141
production 195
Agatston score 93
Air bronchogram 48, 50, 103, 104f, 250f, 429
types of 103t
Air leak 390
Air pollution 32
Air space
cystic 104, 309, 310
pattern 269
Airway 289
disease, small 92f
inflammation, chronic 142
malformation, congenital pulmonary 298, 310
tumors 13, 15, 119, 125t, 302
classification of 119
Alectinib 330
All-trans-retinoic-acid syndrome 279
Alpha-fetoprotein 211
American Academy of Otolaryngology-Head and Neck Surgery 206
American Joint Committee on Cancer 153, 204
staging 345
American Society for Head and Neck Surgery 206
American Thoracic Society 37
Amine precursor uptake 139
Amyloidosis 277, 283, 285
Anaplastic large cell lymphoma 243, 250f
Anaplastic lymphoma kinase 43, 43f, 250f
mutation 353
rearrangements 42
Aneurysm, left ventricular 417
Angiosarcoma 175, 183, 184
Ann Arbor staging system, Cotswolds modifications of 256
Anterior mediastinal mass 198, 245f, 272f, 414, 415f, 416f, 420f, 447f
signs of 414b
Anti-anaplastic lymphoma kinase targeted therapy 387
Antiangiogenic agents 332
Antibodies, pancytokeratin 150
Anti-epidermal growth factor receptor targeted therapy 387
Antimetabolites 386
Antiretroviral therapy 317
Anti-vascular endothelial growth factor targeted therapy 387
Aorta 411
Aortic nodes 73
Apparent diffusion coefficient 10, 202, 227
Arc calcifications 176f
Arsenic 31
trioxide 280
Artery
enlarged pulmonary 410
left pulmonary 136
Artificial intelligence 2022
Asbestos 31
ASKIN tumor 185
Aspergillosis, bronchopulmonary 436
Atelectasis 389
postobstructive 63
Atrium, right 447f
Automated software, use of 87
Autonomic nervous system 225
B
B-cell
lymphoma 241f, 243
diffuse large 160, 172, 242, 249, 253f
intravascular large 249
primary mediastinal 244, 244f, 245f, 246
neoplasm
low-grade 249f
mature 242
Beaded septum sign 266
Bevacizumab 332, 387
Bilobectomy 389
Biopsy 356
endobronchial 126f
Bisphosphonate 77
Bladder 342
Blastoma, pulmonary 140
Bleomycin 367
Bone 274
cyst, aneurysmal 306
destruction 186
Ewing's sarcoma of 185
metastases 77
tumors 17, 183
Bowel disease, inflammatory 285
Brachial plexus 400
Brachytherapy 355
catheter placement 355
Brain metastasis 34
Breast 274, 342
lymphoma 256
Brigatinib 330
Bronchial artery embolization 365
Bronchial wall thickening 142
Bronchiectasis 310
Bronchiolitis obliterans
organizing pneumonia 388
syndrome 279
Bronchoalveolar lavage 278
Bronchopulmonary segments 437, 437f439f
Bronchovascular bundles 389
Bronchus sign, positive 429
Bubble lucencies 48
Bulky disease 258
Bullae emphysema 310
Burkitt's lymphoma 372f
C
Calcification 48, 99, 199, 267
detection 20
Cancer
disposition syndromes 290
registries, population-based 334
solid 322
Cannon ball 265
metastases 266f
Carboplatin 331
Carcinoembryonic antigen 141, 161
Carcinoid 289, 292, 305
atypical 139, 140
syndrome 144, 195
tumor 15, 143, 143f
pulmonary 16f
Carcinoma
adenoid cystic 120, 122, 123f
adenosquamous 41
bronchogenic 95, 318
colloid 39
colorectal 274
embryonal 221
esophagus 407
hepatocellular 320
left lung 14f
lung 14, 59, 342, 409f, 448, 449f
imaging of 45
mucoepidermoid 120, 123, 124f, 292, 305
sarcomatoid 41, 53, 54f, 127, 129f
tonsil 470
Cardiotoxic drugs 283
Cardiovascular disease 93
Carina, involvement of 63f
Castleman's disease 420
Cavitary masses, causes of 432f
Cavitation 102, 266
Cavity 48, 431
Cell
carcinoma, large 38, 41, 52, 119, 334
death ligand-1, programmed 43
neuroendocrine carcinoma, large 139, 140, 148, 149f
Cellular injury, radiation induced 385fc
Central airway 62
invasion 63f
obstruction 349
Central nervous system 35
Central thoracoabdominal mass lesions, differential diagnosis of 405t
Centrilobular nodules, multiple ill-defined 142f
Cephalization 283
Cerebrospinal fluid 339
Ceritinib 330, 387
Cervicothoracic lesions 399
Cervicothoracic mass 399, 403f, 404f
differential diagnosis of 400t
heterogeneous 402f
Cervicothoracic sign 235f, 399, 399f, 414
Chamberlain procedure 36
Chemoembolization 365
Chemoradiation
adjuvant 336
concurrent 336
Chemotherapy 155, 223, 276, 281, 283, 327, 331333, 336, 365
platinum-based doublet 333
Cheson response criteria 381
Chest
pain 33
radiograph 5f, 6f, 144, 161, 168, 170, 176, 198, 212
thymoma 198f
tumors 3, 8t, 349, 356, 370
spectrum of 289
wall 174, 290, 292, 384, 448
invasion 67, 67f, 165f
involvement 164
lesion 176
lipoblastoma of 307f
lipoma 179f
lymphoma 255
mass 9
mesenchymal hamartoma of 305, 306f
soft tissues of 400
structures 17
tumors 13, 17, 157, 174, 175fc, 305, 338
X-ray 233
Chloroma 286
Cholangiocarcinoma 320
Chondroblastomas 17
Chondroid calcification, rings and arcs pattern of 188
Chondroma 129
Chondrosarcoma 176f, 183, 185f, 188, 267f
high grade 17
Choriocarcinoma 221
Chromium 31
Cidofovir 305
Cisplatin 331, 367, 387
Coaxial technique 356
Communications system 112
Computed tomography 151, 161, 169, 170, 178, 179, 183, 184, 213, 218, 224, 342, 349, 386
contrast-enhanced 45, 152
scan 198
technique 7
technique, low-dose 83, 86
Conventional transbronchial needle aspiration 36
Coronary artery calcium 93
Cough 33
Crizotinib 330, 387
Cryoablation 364
Cushing's syndrome 34, 144, 150, 195
Cyst 48, 279, 431
bronchogenic 310
congenital 310
esophageal duplication 420, 422f
fibrotic 310
irregular 279f
neuroenteric 400f, 424f
pleuropericardial 417
post-infective residual 310
pulmonary 133
ruptured dermoid 215f
Cystic lesion, large multiloculated 400f
Cystic mass, multicompartmental 426f
Cytotoxic chemotherapeutic agents 367
D
Deauville scale 260
Decarboxylation 139
Dehydrogenase, isocitrate 280
Delta-like ligand 3 333
Dendritic cell neoplasms 194
Dermatofibrosarcoma protuberans 175, 180
Dermoid cyst 216f, 292, 414, 427
Diaphragm 69
Diaphragmatic movement assessment 201
Diffusion-weighted imaging 10, 202
Distant metastasis stage 167
Docetaxel 386
Doege-Potter syndrome 168
Doxorubicin 367
Doxycycline 367
Driver mutations 42
oncogenic 327
Drop metastasis 271, 272
Dry pleural dissemination 57, 57f, 270
Duplication cyst 405f
Dysphagia 151f
Dysplasia, fibrous 177f
Dyspnea 33
clinical worsening of 282f
E
Eaton-Lambert myasthenic syndrome 150
Echocardiography, transesophageal 255
Ectoderm 212
Ectopic origin, tumor of 138
Edema 277, 283
perilesional 322f
Electromagnetic navigation bronchoscopy 351
Emphysema 92f, 316f
centrilobular 117
paracicatricial 469
scoring 93
Empyema cavity, chronic 253
Enasidenib 280
Encephalitis, limbic 150
Encephalomyelitis 34, 150
Enchondroma 188, 189f
Endobronchial ultrasound 352
guided transbronchial needle aspiration 36
Endoderm 212
Engraftment syndrome 277, 279, 282
Epicardial fat pad 417
Epidermal growth factor
mutation 42, 43f
receptor 26, 42, 328, 353
Epithelial gland, common 125t
Epstein-Barr virus 319
Erdheim-Chester disease 137, 249
Erlotinib 329, 387
Esophageal hiatus 405f
Esophagus 69, 400, 411
European Respiratory Society 85
European Society of Radiology 85
Ewing's sarcoma 175, 185, 186f, 290, 292, 307
extraosseous 185
Extrapleural lesions 395, 396
Extra-thoracic adrenal metastasis 76f
F
Fascicular sign 233
Fasciitis, proliferative 175
Fat 99, 100
density 100f
intralesional 184
Feeding vessel sign 265, 266f
Felson's method 411, 412f
Fibroblastoma, desmoplastic 175
Fibroblasts 300
Fibromas, chondromyxoid 17
Fibromatosis 175, 180, 181f
desmoid type 160
Fibrosarcoma
congenital 308
infantile 290, 308
malignant 175
Fibrosis 13
around large lymphoid cells 245f
idiopathic pulmonary 93, 315, 316f
progressive massive 108f, 315
pulmonary 316f
Fibrotic scars, pleural based 117
Fine needle aspiration cytology 358
Fissures, thickening of 318
Fistula, bronchopleural 390, 396
Fleischner Society guidelines 110, 113
aims of 111
Florid proliferation 141
Fluid bronchograms 45
Fluorodeoxyglucose 24, 122, 147, 310
positron emission tomography-computed tomography 166
Follicular bronchiolitis 249
G
Ga 68-labeled tetra-azacyclododecane–tetra-acetic acid 147
Gallbladder, adenocarcinoma of 270f
Ganglia, sympathetic 422
Ganglion cell 225
tumors 225, 230t, 232, 232t
Ganglioneuroblastoma 225, 228f
Ganglioneuroma 225, 227f, 233f, 425f
Gastroesophageal junction 406f
Gastrointestinal tract 320
Gefitinib 329, 387
Gemangiomas, giant 404
Gemcitabine 331, 386, 387
Germ cell tumors 138, 194, 210, 289, 292, 414
benign 292
classification of 211
malignant 292, 445f
nonseminomatous 211, 220
Glomus tumor 175
malignant 175
Graft versus host disease 279, 285, 322
Granular cell tumor 120
Granulocytes 279
Granuloma, benign 98f
Granulomatosis, lymphomatoid 249
Granulomatous disease 73, 323
Great vessels 68, 68f, 448
Gross tumor volume 340
Ground-glass
attenuation 434f
components 429
nodules 47, 96f
multifocal 79
opacities 112, 267, 277, 287f, 314, 318, 433
Growth rate 98
H
Halo sign 48, 97, 429
reverse 97, 97f, 97t
Hamartoma 100f, 120, 430
congenital mesenchymal 292
fibrous 402f
mesenchymal 290
pulmonary 128130, 130f, 289, 292
Head and neck squamous cell carcinoma 274
Heart 68, 448
Hemangioendothelioma, epithelioid 128, 134, 160, 175
Hemangioma 120, 175, 184, 189, 289, 290, 292, 302, 303f, 305
infantile 302
subglottic 302, 303f
Hematopoiesis, extramedullary 424
Hematopoietic stem cell transplantation 276, 322
Hemidiaphragm elevation 198
Hemoptysis 33, 354
massive 354
Hemorrhage 267, 277, 282
diffuse alveolar 283
pulmonary 283, 284f, 389
Hernia, post-traumatic diaphragmatic 407f
Hilar
angle sign 410
enlargement, causes of 408t
mass 406, 407fc, 408f, 409f
nodal enlargement 409f
Hilum 69
bronchi of 410
convergence sign 410, 410f, 414
negative 410
positive 410
overlay sign 408, 408f, 414
Histiocytic disorder 137
Histiocytoma, benign fibrous 175
Hodgkin's disease 293
Hodgkin's lymphoma 242, 243, 246, 256, 258, 273, 319, 319f, 323f, 422f
classic 243f, 244f, 251f, 259f
Horner's syndrome 49, 346
Hounsfield units 178
Human epidermal growth factor receptor 2 43
Human herpes virus 8 172
Human immunodeficiency syndrome 317
infection 319f
Human papilloma virus 304
Humeral mass, right 268f
Hyperbilirubinemia 280
Hypercalcemia 34
Hyperplasia 139t
atypical adenomatous 38
giant thymic 418f
Hyperprogression 382
Hypertension, pulmonary 282
I
Immune
checkpoint inhibitors 327
partial response 382
reactivation inflammatory response 318
stable disease 382
Immunoglobulin light chain fragments 285
Immunohistochemistry 41, 140
Immunotherapy 330, 333
Infection
active 95
chronic 285
Inflammation
active 95
chronic 32, 172, 160, 253
Inoperable cancer, early stage 338
Interferons 367
Interleukins 367
International Association for Study of Lung Cancer 73, 152
International Early Lung Cancer Action Program 84
International Germ Cell Cancer Collaborative Group 219
International Germ Cell Consensus Classification 219
International Society for Study of Vascular Anomalies Classification 174
International Thymic Malignancy Interest Group 193, 203, 412
Interstitial pneumonia
imatinib-induced 282f
nonspecific 331, 388
Intrapulmonary node 98f, 105
Ivosidenib 280
K
Kaposi's sarcoma 289, 292, 317, 318f, 320
virus 172
Kirsten rat sarcoma
mutation 43
virus 54
Kulchinsky cells 141
L
Lambert-Eaton myasthenic syndrome 34
Langerhans cell 137
histiocytosis 17
pulmonary 137, 249
Laryngeal nerve palsy 161
Larynx 304
Laser ablation 305, 364
Lateral thoracoabdominal lesion 407f
Leiomyoma 175
benign metastasizing 430
Leiomyosarcoma 126, 126f, 175
Lesion
nonmeasurable 375f
types of 396, 401, 405
Leukemia 241, 276, 289
acute
lymphoblastic 277
myeloid 277
promyelocytic 279
chronic myeloid 281
T lymphoblastic 242
Leukemic cell lysis pneumopathy 277, 279, 281
Leukemic pulmonary infiltration 277, 278
Leukostasis 277
pulmonary 277, 278f
Light chain deposition disease 278
Lipid-Laden histiocytes 137
Lipoblastoma 189, 290, 292, 306, 307
Lipoblastomatosis 189, 292, 306
Lipoid pneumonia 100f
Lipoma 175, 177, 178, 178f, 189, 290, 292
intramuscular 179f
Lipomatosis 175
Liposarcoma 178, 180f, 189
malignant 175
well-differentiated 175
Liver metastasis 33
Lobectomy 344, 389
post-left upper 390f
Locoregional disease 77
Locoregional invasion 173
Lorlatinib 330
Low kilovoltage peak radiograph 176
Lower thoracic esophagus 406f
Lugano classification 256
Lugano system 256
Lung 265, 289, 320, 448
abscess 432
adenocarcinoma 374f
pseudoprogression in 381f
apex tumor 49
biopsy 39f
transbronchial 141
cancer 27, 31, 37, 45, 309, 318, 320, 322, 327, 334, 343b, 353, 371f, 381, 430, 433, 434, 435
clinical manifestations of 33t
contiguous spread of 57f
development of 31, 83
imaging of 396, 428
locally advanced 345
majority of 35
mimicking organizing pneumonia 433
paraneoplastic manifestations of 34t
pneumonic type 80f
resection, primary 77
risk factors for 32t
screening 83, 92
second primary 78, 79f
staging of 12
study of 203
carcinoma 12, 13, 45, 48f, 309, 310
central 46f
driver mutations of 37
immunohistochemistry of 37
pathology of 37
peripheral 47f
disease
cystic 277, 278
interstitial 138
localized 77
occupational exposure-related 314
extranodal marginal zone lymphoma of 250f
infarction 390
injury, gemcitabine-induced 388f
involvement, bilateral 53
irradiation 384
lesions 395
bilateral 372f
lymphomas, common 252t
malignancy 342
mass
central 145f
large peripheral 357f
metastases 17, 17f
nodules 9
management of 351
normal 384
parenchyma 55, 169f, 390
large pleomorphic lymphocytes invading 250f
parenchymal
lesions 395
lymphoma 249
RADS categories 88t
scar cancer 313, 314
superior sulcus of 400
torsion 390
toxicity, radiation induced 385f
tumors 119, 127
central 344f
classification of primary 37
primary 37fc
staging of 58
Lymph nodal
disease 273
dissection 345
enlargement, lobulated 408f
measurement 371
Lymph node 206, 336, 353f, 400, 408, 448
involvement descriptors 206
left lower paratracheal 208f
metastases 55
pathological 380
right axillary 323f
staging 72
stations 258
subcarinal 323f
Lymphadenopathy 318
massive 423
metastatic mediastinal 273
Lymphangioleiomyomatosis 132, 133f, 292, 301
Lymphangioma 426f
Lymphangiomatosis, diffuse pulmonary 296
Lymphangitic spread 266
Lymphangitis carcinomatosa 55, 267f, 375f, 436f
Lymphatic
dissemination 187
malformation 400f
manifestations 134
site lymphoma 242
Lymphocytes
immature 245f
small 250f
Lymphohistiocytosis, hemophagocytic 277, 283, 285, 286f
Lymphoid
neoplasms 276
tissue, bronchus-associated 249
Lymphoma 194, 241, 242, 245f, 250f, 252, 254, 259t, 273, 276, 289, 292, 293, 409f, 415, 430, 434, 435
acquired immunodeficiency syndrome-related 249, 251
cardiac 255
common
mediastinal 246t
pleural 253t
Deauville scoring for 260t
disseminated 253
esophageal 254, 254f
Lugano staging of 258t
lymphoblastic 245f
primary effusion 160, 171, 253
recurrent 260
response assessment of 258
staging of 256
T lymphoblastic 242
types of 260
WHO classification of 241, 242t
Lymphoproliferative disorder 160, 171, 276, 420
M
M1a-bilateral disease 79
Magnetic resonance imaging 3, 8, 165, 169, 171, 177179, 183, 184, 200, 214, 218, 227, 272
contrast-enhanced 214
techniques 9
Malformations, arteriovenous 305
Malignancy
extrathoracic 273
hematologic 276, 287f
primary 95
Malignant mesothelioma
solid tumors for 378
tumor measurement of 379f
Malignant nodule 429t, 430f
pleural tags in 103f
Malignant pleural infiltration, thoracoscopic image of 354f
Malignant vascular lesions 184t
Mammary artery, internal 447f
Masaoka-Koga staging system 203, 208, 209t
Mass 428, 431
cardiac 421
cardiophrenic angle 417, 420f
central 151, 473
common mediastinal 247t
cystic
anterior mediastinal 418f
cervicothoracic 400f, 401f
homogeneous 404f
hyperdense 417
hyperechoic 301f, 303f
intrabronchial 145f
irregular margin of 198
large
hypodense 268f
solid 316f
left upper lobe 373f
lesions 48
malignant 292
multicompartmental solid 426f
non-neoplastic 430t, 432t
peripheral 151
pulmonary 397t, 408
hilar 406
right
adrenal solid 426f
suprarenal 273f
solid 421, 424
true hilar 407, 410
vascular 427
Mature cystic teratoma 293f
dermoid cyst 214f
Mature teratoma 212, 217b
benign 414, 427
magnetic resonance imaging features of 216b
Mediastinal
compartments 412f
structures of 413t
cystic mature teratoma, anterior 213f
emphysema 391
extension 45, 303f
fat 69
immature teratoma, anterior 213f
invasion 162
lymph node
metastases 273f
sampling 352
lymphadenectomy, transcervical extended 36
lymphadenopathy 321, 409f
lymphoma 242
WHO classification of 242
mass 8, 9, 359, 408, 411, 414, 415, 420, 443, 444, 446
heterogeneous anterior 208f
infiltrative 445f
lobulated homogeneous anterior 195f
posterior 227f, 228f, 422, 423, 423f, 424f, 424t
sampling 360f
signs of 410f, 421b, 423b
smoothly marginated anterior 244f
solid anterior 418f, 419f
solid middle 422f
solid posterior 425f
nerve sheath tumors 235f
neurofibroma 237f
nodes
extensive 153f
inferior 73
superior 73
pleural involvement 271f
seminoma, anterior 220f
structures 443, 448
teratoma, immature anterior 217f
tumors 191, 292
widening 415
Mediastinoscopy 36, 342, 352
Mediastinum 69, 258, 289, 384, 411
anterior 290, 412f, 427f
compartments of 411, 412t
middle 290, 412f
posterior 292
surgical staging of 342
Melanoma 138, 274, 342
Meningioma 138
Mesoderm 212
Mesothelial tumors 159, 160
Mesothelioma 13, 14, 15f, 162f, 164f166f
diffuse malignant 159
malignant 379t
pleural 160, 162f
with asbestosis 163f
Metachronous disease 77
Metastasis 152, 172, 430
adrenal 34, 77
calcified mediastinal nodal 272f
cavitary 267f
endobronchial 269
evaluation of 15
extrathoracic 448
hematogenous 55, 266f
multiple distant site 77f
pleural 65, 66f, 270
pulmonary 164, 268f, 274f
parenchymal 265
skeletal 33
solitary 269
staging 76
Metastatic disease 76
part of 63
Metastatic evaluation, thoracic computed tomography for 274
Metastatic nodes 273
Microwave 363
Middle lobe bronchus, right 124f
Middle mediastinal
extension 426f
mass 420, 421f
classification of 421t
Miliary metastases 270, 270f
Minimally invasive surgery 389
Monoclonal antibody 77
Morgagni hernia 417
Mucin stains 41
Mucosa-associated lymphoid tissue 242
lymphoma 249
Multicompartmental mass 423, 425f
classification of 426t
Multidetector computed tomography 6, 144, 177
Multifocal micronodular pneumocyte hyperplasia 134, 301
Multiple neuroendocrine neoplasia 195
Muscle
infraspinatus 182f
intercostal 67f
large mass involving 256f
tumors, skeletal 175
Myasthenia gravis 195f, 202f, 203f, 411
Myeloablative total body irradiation 322
Myeloid
dendritic cells 137
neoplasms 276
sarcoma 286, 287f
Myeloma, multiple 184, 276, 279f
Myocardium, nodular thickening of 255f
Myofibroblasts 300
Myositis ossificans 175
Myxoid sarcoma, pulmonary 124, 126f
N
Napsin-A 41
National Cancer Institute 327, 371
National Comprehensive Cancer Network 181
National Lung Screening Trial 84, 85
Neck, soft tissues of 399
Necrotic mediastinal nodes 273f
Nederlands-Leuvens-Longkanker Screenings Network 84
Nelson trial 85
Neodymium-doped yttrium aluminum garnet laser 364
Neoplasms
benign 292, 296
malignant 293, 296
primary pulmonary 428, 434, 435
Nephroma, cystic 297
Nerve
sheath 225, 400
tumors 175, 232, 232t, 238t
subscapular 239f
Neural network model 22, 23f
Neuroblastoma 225, 227, 229f, 290, 292, 294
abdominal 294
adrenal 273f
retroperitoneal 294f
Neuroendocrine cell hyperplasia 142f
diffuse
idiopathic pulmonary 139, 142
intrapulmonary 140, 141
Neurofibroma 175, 189, 232234, 236, 236t, 238, 239f, 289
large 10f
multiple tiny 10f
Neurofibromatosis 239f
Neurogenic tumors 120, 422
classification of 224, 225t
malignant 292
Neurolysis 369
Neuropathy 34, 150
Neutropenia, febrile 48
Nickel 31
Nintedanib 332
Nodal Hodgkin lymphoma, treated 257f
Nodal lymphoma 242
Nodal metastases 72f
location of 72t
Nodal stations 74f
Nodular opacities 310f
Nodular pleural thickening 198, 271f
Nodular sclerosis 242
Nodule 48, 113fc, 318, 428
benign 429t
density of 53, 96f
incidentally-detected 116, 451f
location of 100t
management of 116
measurement technique 111
miliary pulmonary 270f
morphology 86
multiple
peripheral 266f
solid 116
subsolid 116
neoplastic 430t, 432t
part solid 47
perifissural 106f
perilesional centrilobular 432
perilymphatic 267f
pleural 253
shape of 98
single solid 114
size 96
solitary pulmonary 12, 94, 131
subcutaneous 257f
subsolid 115
Non-Hodgkin's lymphoma 242, 244, 293, 293f, 323
Nonmetastatic extrathoracic disease 76
Nonpleural disease 379
Nonsmall cell carcinoma 139
classification of 38t
Nonsmall cell lung cancer 59, 148, 328, 334, 343, 352, 360
advanced 332fc
early 343
management of 335
metastatic 337
treatment strategies for 338t
Nonvascular palliative procedures 366
NUT carcinomas 197
O
Obstructive pulmonary disease, chronic 93, 141
Occipital lobe, right 322f
Oligometastases 76
Operable cancer, early stage 338
Osteoblastomas 17
Osteochondroma 176, 177f, 188, 290
Osteoid osteomas 17
Osteosarcoma 187, 187f, 188, 269f, 290, 292, 307
femoral 268f
humeral 268f
metastatic humeral 268f
Ovarian epithelial neoplasm 274
P
Paclitaxel 331, 386
Pancoast syndrome 33, 49
Pancoast tumor 49, 49f, 337, 346, 347b, 347f
subclavian vessels in 68f
Papillomas 121, 304
formation of
multiple 304
recurrent 304
squamous 120, 289
Paraesophageal lymph nodal involvement 164
Paragangliomas 228, 231f, 420
Parahilar mass, right 373f
Paraneoplastic manifestations 31, 34, 35
Paraneoplastic syndrome 144, 150, 195
Parasympathetic system tumors 228
Parenchymal lesion 398
PEComatous tumors 128, 129, 132
Pectoral nerve, medial 239f
Pediatric chest tumors 289
spectrum of 289
Pediatric thoracic tumors, spectrum of 289t
Pembrolizumab 331
Pemetrexed 331, 387
PERCIST criteria 378
Percutaneous aspiration cytology 356
Pericardium 68, 448
Pericystic tumors, types of 312f
Periodic acid-Schiff 285
Peripheral nerve sheath tumor 235f
malignant 175, 232, 237, 238f
Peripheral pulmonary
arterial branches 278f
lesions, localization of 437
nodules 351
Peyer's patches 241
Philadelphia chromosome 281
Phleboliths 184
Phrenic nerve 239f
palsy 198, 237f, 445f
Pierre-Marie-Bamberger syndrome 168
Placental alkaline phosphatase 211, 218
Plasma cell
disorders 276
dyscrasia 277, 278
Plasmacytoma 184
multiple 185f
Pleura 159, 384, 448
calcifying tumor of 171
Pleural disease 63
bilateral 380
characterization of nonmeasurable 380
nonmeasurable 380f
Pleural effusion 33, 66, 163f, 253, 281, 288
bilateral 318
malignant 353
Pleural fluid drainage 366
Pleural invasion 63, 64f
computed tomography criteria for 64
Pleural lymphoma, secondary 253
Pleural lymphoproliferative disorders, WHO classification of 253
Pleural mass 397t
evaluation 172
Pleural tumors 159
classification of 159
Pleurectomy, surgical 368
Pleurodesis 367
Pleuroperitoneal shunt 368
Pleuropulmonary blastoma 289, 290, 292, 296, 297f, 298f, 310, 310f, 431
types of 299t
Plexiform
fibrohistiocytic tumor 175
neurofibroma 175, 234, 237f, 402f
Pneumocystis jirovecii pneumonia 319
Pneumocytes 388
Pneumocytoma 430
sclerosing 127, 128f, 289, 292
Pneumomediastinum 390
Pneumonectomy 343, 344f, 389
Pneumonia
cryptogenic organizing 331
eosinophilic 389
interstitial 281, 311f, 331
lymphocytic interstitial 249
organizing 433
Pneumonitis
hypersensitivity 331
immunotherapy-induced 331
Pneumothorax 268f, 390
spontaneous 161, 389
Polycyclic aromatic hydrocarbons 31, 314
Positron emission tomography 352
computed tomography 12, 147
response criteria 378
role of 414
Postlung resection pulmonary edema 391
Postoperative radiation target volume 335
Postpneumonectomy syndrome 391
Postradiofrequency ablation complications 391
Postrenal transplant 322f
Post-transplant lymphoproliferative disorder 241, 242, 251, 320, 321f
Preinvasive lesion 139
Primordial germ cells, differentiation of 211fc
Progressive disease 259, 380
Prophylactic cranial
irradiation 338
radiotherapy 155
Prostate 342
specific membrane antigen 18
Protein, serum soluble mesothelin-related 161
Proteinosis, pulmonary alveolar 277, 283, 285
Proton therapy 384
Pseudocavitation 48, 103
Pseudoextension 404
Pseudomasses 396
Pseudoprogression 381
Pulmonary artery 136f, 390
branches 410f
intimal sarcoma 129, 135
right 136
Pulmonary edema 283, 284f
acute noncardiogenic 391
Pulmonary function test 315
Pulmonary lesions 395
pre-existing 309
Pulmonary lymphohistiocytic tumors, WHO classification of 249
Pulmonary lymphoma
primary 250
secondary 251
Pulmonary nodules 94, 108, 134, 450
evaluation of 94
Q
Quantitative vessel tortuosity 27
R
Radial endobronchial ultrasound 351
Radiation
delivery methods 384
dose 87, 336, 338
fibrosis 386, 386f
ionizing 32
pneumonitis 385, 386
techniques 337
therapy 155, 334, 384
planning 13
three-dimensional conformal 337
treatment 339
volume 338
Radical radiation 336
Radiofrequency ablation 362, 389
computed tomography guided 362
Radiogenomics 23, 25
Radiomics, role of 26
Radiotherapy 183, 365
intensity-modulated 337
postoperative 208, 336
Ramucirumab 332
Regional lymph nodes stage 167
Renal cell carcinoma 266f, 274, 469
Renal failure, acute 280
Renal mass, left 266f
Respiratory papillomatosis, recurrent 121, 304, 304f
Reticulonodular opacities 319f
Retinoic acid syndrome 279
Rhabdomyoma 175, 292
cardiac 301, 301f
Rhabdomyosarcoma 175, 290, 292
Rheumatoid arthritis 285
Rib 400
changes 176
erosion 57f
Right main bronchus 350f
Rings and arcs mineralization 176
Rokitansky protuberances 212
Rosai-Dorfman disease 423
Round cell tumor 404f
Rovalpituzumab tesirine 333
S
Salivary gland
common 125t
tumors 122
Sarcoidosis 267f, 436
Sarcoma 120
inflammatory myofibroblastic 175
undifferentiated pleomorphic 180
Scar carcinoma 49, 102, 313
Schwannoma 175, 232, 233, 236, 236t, 238, 289
cystic 234, 234f
intercostal 235f
Sclerosis, tuberous 133f, 291, 301, 301f
Segmentectomy 389
Seminoma 216
Septal thickening 318
Serum amyloid 285
Sibson fascia 399
Silhouette sign 414, 423
Sinus histiocytosis 423
Sleeve resections 344, 389
Small cell carcinoma 119, 139, 140
Small cell lung
cancer 59, 149, 153t, 333, 334
carcinoma
management of 337
treatment for 339t
Small peripheral lung nodule 357f
Smooth muscle
actin 126
tumors 175
Soft tissue
bilateral paravertebral 294f
component 179f
large 186f
intrabronchial 145f
mass 256f
neck 302
proliferation 184, 189
sarcomas 18, 181, 274
tumors 177
window 99
Solid lesions 35, 417
Solid nodule 48
size of 112f
Solid organ transplant 320
Solid tumors 371, 378
criteria, response evaluation criteria in 376
immune response evaluation criteria in 382
Solitary fibrous tumor 160, 168, 168f170f, 175, 290, 398f
Specific tumor types 49, 141
Spine sign 423
Splenic hydatids 404
Split-fat sign 234
Squamous cell carcinoma 37, 40, 40f, 41, 47f, 52, 53t, 102, 102f, 119, 121f, 197, 197f, 313f, 316f, 322, 374f, 406f
left upper lobe 398f
thymic 197f
Stable disease 373f
Stereotactic ablative body radiotherapy 336
Stomach
adenocarcinoma of 271f
herniation of 407f
Stratified squamous epithelium 304
Subclavian vein, right 403f
Sublobar resection 344, 389
indications of 345b
Subpleural blebs 310
Sulcus tumor, superior 45, 49, 346, 399f, 403f
Supraclavicular fossa 336
Surgery 155, 367
Syndrome of inappropriate antidiuretic hormone secretion 150, 195
Synovial sarcoma 160, 169, 171f
Systematic mediastinal lymph node
dissection 345
sampling 345
T
T and NK neoplasms, mature 242
T cell lymphoblastic lymphoma 245f, 246
Taxanes 386, 387
Tension pneumothorax, development of 390
Teratomas 212, 290
immature 214, 217b, 217f
Testicular microlithiasis 221f
Tetracycline 367
Thoracic
cavity 294f
duct 411
germ cell tumors, imaging of 210
inlet 399
involvement 276
lymphoma 241
malignancies 309
masses 12, 395, 395fc
metastasis 265, 273, 274t
imaging of 265
nerves 239f
anatomy of 226t
neuroblastoma 294, 295b, 295f
neuroendocrine tumor, classification of 139t
spine 400
surgery, robotic-assisted 343
tumors 13b, 13t, 290, 291, 291t, 443
acquired immunodeficiency syndrome-related 317fc
Thoracoabdominal lesion 404
central 405f, 406f
Thoracoabdominal mass, homogeneous 405f
Thoracoabdominal sign 294f
Thoracocentesis 362
Thorax 12, 242
important nerves of 224
neuroendocrine tumors of 139
neurogenic tumors of 224
Thrombocytopenia 283
Thymic carcinoma 13, 194, 195, 197, 200f, 208f
advanced stages of 199t
Thymic epithelial tumors 13, 193
imaging of 193
Thymic hyperplasia 199, 202, 202f, 203f, 414
post-treatment 260
Thymic mass, homogeneous 195f
Thymic neuroendocrine
neoplasms 198
tumors 194, 195, 203
Thymolipoma 417
Thymoma 13, 14f, 194, 195f, 196, 197f, 201, 201f, 202, 272f, 373f, 414, 417
carcinoma, advanced stages of 199t
intrapulmonary 138
invasive 200f
types of 196t
Thymus 193
epithelial neoplasms of 194t
Thyroid 400
transcription factor 1 41, 140
Tissue, subcutaneous 256f
Total parenteral nutrition 283
Trachea 121f, 411
adenocarcinoma 122f
anterior margin of 412f
carcinoma of 16f
displacement of 421f
Transbronchial needle aspiration 351
Transmanubrial L-shaped approach 346
Transthoracic needle aspiration, computed tomography guided 36
Trimodality therapy 336
Tuberculosis, active 432
Tumor 290
adipocytic 175, 177
advanced 150
atypical lipomatous 175
benign 175, 188, 188t
malignant neurogenic 292
metastasizing 269
biopsy 13
bulk, reduction of 305
calcifying fibrous 160
cartilage 183
cells 141, 217
central 45, 144
chondroid 176
congenital peribronchial myofibroblastic 292, 300
descriptors, primary 59
desmoid 180
desmoplastic round cell 140, 160
diameter, maximum 65f
dysembryonic 290, 296
dysontogenetic 290
ectopic thymic 203
embolism 270
embryonal 290
endobronchial inflammatory myofibroblastic 131f
epithelial 120, 127
fat containing 189
fibroblastic 175
fibrohistiocytic 175, 180, 182f
gastrointestinal stromal 175
groups 175
high-grade 139
inflammatory myofibroblastic 124, 129, 131, 292, 300, 300f, 430
intensity histogram 24
intermediate 139, 175
involving airways 120t
low-grade 139
lymphocytes 250f
lymphohistiocytic 136
malignant 175, 188, 188t
mesenchymal 124, 127, 168
metastatic 273
mucinous 51, 52
multiple sites of 78
myofibroblastic 175, 289
negative 55t
neuroendocrine 119, 121, 139, 193, 334
node metastasis
classification 78
staging 204
nodule 70, 70f, 78
peripheral 46, 144, 146
positive 55t
primary 61f, 111
pulmonary 296
primitive neuroectodermal 140, 185, 186f
proliferative index of 140
recurrence of 13
region-specific 292
size 60
measurement 60f
specific primary 177
staging of 13
sympathetic system 228
unique pediatric 290
vascular 183
volumetry 380
Typical carcinoid 139, 140, 145f, 146f
Tyrosine kinase inhibitor
effects 277, 279
related complications 281
U
Ultrasonography 4, 176178, 213
role of 414
techniques 4t
Ultrasound 166
endoscopic 352
Unilobectomy 389
Union for International Cancer Control 204
United States Immune Deficiency Network Registry 323
Upper lobar fibrosis, bilateral 469
Upper lobe
adenocarcinoma, right 398f
bilateral 137f
bronchial stump 344f
mass abutting chest wall, right 67f
V
VALSG system, modified 151f, 152
Vascular convergence sign 104
Vascular lesions, benign 184t
Vascular malformation 184, 189, 427
Vasculitis 95
Vena cava
inferior 411
involvement of superior 151
obstruction, superior 161
stenting, superior 365
superior 33, 216, 244f, 365
Vessels, pulmonary 408
Video mediastinoscopy 36
Video-assisted mediastinoscopic lymphadenectomy 36
Video-assisted thoracic surgery 343
Video-assisted thoracoscopic
guided biopsy 351
lobectomy 389
surgery 389
Videoscopic assistance 347
Virtual bronchoscopy navigation 351
Visceral pleural invasion 64f
Voice, hoarseness of 33
W
Waldeyer's ring 258
Warts 304
Wedge resection 389
Wet pleural dissemination 270, 271f
Wilms’ tumor 274f
World Health Organization 119, 370
classification 174, 193
Wrap around sign 255
X
X-ray 183
Y
Yolk sac tumor 221
Z
Zoledronic acid 77
×
Chapter Notes

Save Clear


1Imaging Modalities
  1. Imaging Modalities in Chest Tumors: Role and Techniques
  2. Role of PET-CT in Chest Tumors
  3. Artificial Intelligence and Radiomics: Basics and Applications2

Imaging Modalities in Chest Tumors: Role and TechniquesCHAPTER 1

Devasenathipathy Kandasamy,
Gh Mohammad Wani
 
INTRODUCTION
There are battery of investigations available to the radiologists to evaluate the chest diseases. Most commonly used modalities are plain radiography, ultrasonography (USG), computed tomography (CT), and magnetic resonance imaging (MRI). In each of the modalities there are different techniques which can be used to get the maximum information in the given clinical context. Hence, the complete understanding of the strengths and weaknesses of the modalities and various techniques is vital to maximize their utility. In the context of chest tumors, the primary role of imaging is detection, characterization, staging, and follow-up after treatment. Each modality has its own advantages and limitations which will be discussed below.
 
PLAIN RADIOGRAPHY (FIGS. 1 TO 4)
 
Role
  • Used as initial screening modality for respiratory complaints and guides further imaging
  • Not good for staging of tumors as it cannot assess lymph node, chest wall, or mediastinal invasion
  • Used in respiratory emergencies in intensive care unit (ICU) and bedside
  • Screening for metastases and complications related to disease and treatment
  • Follow-up of lung nodule to assess the doubling time.4
 
Techniques
Table 1   Radiographic techniques.
Technique
Comments
Chest radiograph: Posteroanterior (PA) view
  • Standard technique
  • Most commonly performed
  • Most of the measurements and signs described on radiographs apply to this view
Chest radiograph: Anteroposterior view
  • Performed when patient cannot be positioned for PA view such as in ICU, bedside and children
Chest radiograph: Penetrated view
  • Usually performed to better visualize mediastinal structures, calcification in the mass lesion and to look for rib erosion
Chest radiograph: Lateral view
  • Rarely performed-not a standard part of chest imaging except in few centers around the world
  • CT has almost replaced this view
Lordotic view (Apicogram—if only the apices are included)
  • Specialized view to demonstrate the apices of lungs which are usually hidden behind the clavicles on routine views
  • CT has almost replaced this view
Oblique view of chest
  • Rarely performed
  • Useful in showing chest wall or pleural masses
  • CT has almost replaced this view
Dual energy subtraction radiography
  • Two energy (high and low) rays are used to create three types of images (standard image, soft tissue selective image and bone selective image). By removing overlapping soft tissue or bony structure depending on the image type it is superior in demonstrating tiny areas of calcification, pleural lesions, soft tissue lesions and hilar structures
 
ULTRASONOGRAPHY
 
Role
  • There are evolving roles with newer indications appearing regularly, particularly important in children
  • Used to assess mediastinal lymph nodes and to guide sampling in children
  • Normal thymus/hyperplasia vs mediastinal mass in children (Figs. 1A and B)
  • Cystic versus solid differentiation (lung cysts, hydatid, etc.) (Figs. 2A to C)
  • May be the only modality required in several benign chest wall masses.
 
Techniques
Table 2   USG techniques.
Indication
Probe
Approach
Any special technique
Chest wall masses
Linear, high frequency 9–15 MHz
Direct
Standoff pad/gel
Mediastinal masses
Convex sector or endocavitary probe
Subxiphoid, suprasternal or parasternal
Insonate through the intercostal spaces in the parasternal region5
Pleural pathology
(effusion, pneumothorax, mass)
Curvilinear or sector probe
Direct
  • Look at posterior costophrenic angle in erect position for minimal free effusion
  • Look at nondependent regions for pneumothorax
  • Look for pleural sliding to evaluate tumor infiltration of chest wall
zoom view
Figs. 1A and B: Chest radiograph frontal view (A) of a child with asthma showed a mass like opacity in the anterior mediastinum. USG using a high resolution linear probe (B) was performed (arrow) to rule out a mass lesion which showed a soft tissue in the prevascular region with a typical starry sky appearance suggestive of thymus.
zoom view
Figs. 2A to C: Chest radiograph of a patient (A) showing opaque hemithorax with ipsilateral shift of mediastinum. USG of the right lung (B) showing an area of dense calcification (thin arrow). These findings were also confirmed on CECT scan (C). The patient underwent right pneumonectomy and the lesion was diagnosed as carcinoid on histopathology.
6
  • Standard linear and convex probes are the most commonly used
  • Small footprint probes should be used if the acoustic window is small
  • Conventional gray scale USG with color Doppler wherever vascularity assessment is necessary
  • Elastography of pleura has been found to improve characterization of lesions
  • Contrast-enhanced ultrasound (CEUS) can add on to gray scale and color Doppler in the evaluation of masses.
 
MULTIDETECTOR COMPUTED TOMOGRAPHY
 
Role
  • It is the workhorse of thoracic imaging especially in the characterization and staging of tumors (Figs. 2 and 3).
zoom view
Figs. 3A to C: Chest radiograph (A) of a patient showing a large mass lesion silhouetting the left cardiac and diaphragmatic border; (B and C) CECT scan of the patient (arrow) showing a large soft tissue mass arising from the anterior chest wall with a large extra- and intrathoracic component.
zoom view
Figs. 4A to C: Chest radiograph (A) of a patient with left upper chest pain showing a thick-walled cavity (arrow) seen in the left upper lobe; (B and C) CECT scan confirmed the presence of cavitatory mass lesion with air fluid level. Sampling of the mass revealed squamous cell carcinoma of lung.
  • Ability to show the body structures in cross section, faster acquisition, and thin slice acquisition has revolutionized chest imaging (Figs. 4A to C).
  • Although many new techniques are currently available to reduce radiation dose, it is still a major concern.7
 
Techniques and their Indications
Table 3   CT techniques and indications.
CT scan technique
Indication
Noncontrast CT (NCCT)
NCCT
(standard dose 120 kVp, 150 mAs)
  • Lung parenchymal evaluation
  • Screening for metastasis
  • Postchemotherapy and radiotherapy changes
  • In patients with renal impairment
LDCT: Low-dose CT
(90–120 kVp, 30–50 mAs)
  • Lung cancer screening
  • Follow-up of lung parenchymal abnormalities
ULDCT: Ultra low-dose CT
(80–100 kVp, ~20 mAs)
  • Follow-up of solid pulmonary nodule >2 mm
Contrast-enhanced CT (CECT)
CECT
(standard dose 120 kVp, ~150 mAs)
  • Workhorse of chest tumor evaluation for characterization and staging (T, N and M)
  • Can also evaluate lung parenchyma
  • Multiplanar reformat and 3D volume rendering
Perfusion CT (Figs. 5 and 6)
  • Evaluation of first pass contrast kinetics
  • Assessment of neoangiogenesis, response to therapy, etc.
  • Patlak plot or deconvolutional models are commonly used mathematical models
Dual energy CT
  • Provides morphological and functional information of tumors
  • Potential to show iodine-based perfusion maps
Cardiac/respiratory-gated CT
  • Useful to assess chest wall, diaphragmatic, and mediastinal invasion by demonstrating sliding of structures
zoom view
Figs. 5A to C: Perfusion CT (A) of a patient with left upper lobe lung carcinoma showing an enhancing mass lesion (outlined arrow) with a central area of necrosis (thin arrow). The parametric maps showing blood flow (B) and blood volume (C), both of which are showing drastic reduction in the central necrotic area.
8
zoom view
Figs. 6A to C: Perfusion CT (A to C) of a patient with right lung mass showing the role of blood flow and blood volume maps (B and C) in differentiating mass lesion from atelectatic lung which is otherwise challenging just based on gray scale image (A). The thin arrow shows the mass lesion whereas the outlined arrow shows the atelectatic lung.
Standard single phase CT protocols for chest tumors
Table 4   Standard single phase CT protocols for chest tumors.
Tube voltage
100 (<~80 kg)
120 (~80–113 kg)
140 (>113 kg)
mAs
130–200
Collimation of detector
Lowest possible on the scanner (e.g. 0.6)
Beam pitch
1.2
Gantry rotation time
0.5 seconds
Reconstruction slice thickness
1.2–1.5 mm
Image matrix
512 × 512
Radiation dose
3–8 mSv
Contrast
300 mg/mL iodine
Nonionic contrast
Timing of scan
70 seconds after injection
Reconstructions
  • Lung window (soft tissue and high-resolution kernel)
  • Mediastinal window
  • Bone window
 
MAGNETIC RESONANCE IMAGING
 
Role
  • In patients with compromised renal function—noncontrast MRI is superior to noncontrast CT (NCCT).
  • Cardiac MRI is the modality of choice for suspected myocardial involvement by tumors (mediastinal masses).
  • Differentiation of thymic hyperplasia from thymoma using chemical shift imaging.
  • Equivocal chest wall, diaphragmatic or mediastinal invasion can be evaluated on cine MRI.
  • Chest wall masses without bony involvement on clinical/chest X-ray (CXR)/USG assessment—for their characterization and extent.9
  • Posterior mediastinal masses especially to evaluate spinal canal invasion.
  • Lung nodules—follow-up/characterization of likely benign nodules in children and young patients.
  • Brain metastases in patients with carcinoma lung are best evaluated with MRI.
 
Sequences and their Indications
A building-blocks approach is used when planning thoracic MRI.
Table 5   MRI sequences and indications.
Indications
Sequences
Chest wall mass
  • Fast spin-echo (FSE) T2 fat-saturated or short tau inversion recovery (STIR)
  • T1 fat-saturated postcontrast
Mediastinal mass
  • FSE T2 fat-saturated or STIR
  • T1 fat-saturated postcontrast
Lung nodules
  • Gradient recall echo sequences—2D or 3D, short- or ultra-short
  • Spoiled gradient echo sequences
  • Postcontrast: 3D gradient recalled T1 fat-saturated
  • Coils:
    • For large intrathoracic masses—body coil (phased array)/cardiac coil
    • Chest wall masses—surface coils.
  • Breath hold sequences whenever feasible, as respiratory and cardiac gating substantially increases examination times. However, respiratory gating is required for all nonbreath hold sequences. Cardiac gating is required depending on the location of the mass.
  • Methods of respiratory gating: External devices, e.g. pneumobelts, navigator sequences.
  • Some useful free-breathing sequences for patients unable to hold breath including young children: Radial k space-based sequences such as T2 PROPELLER/BLADE.
  • Contrast: Macrocyclic agents, e.g. gadobutrol (Gadovist), gadoterate (Dotarem) are preferred, especially in children.
 
MRI Techniques and Indications
Table 6   MRI techniques and indications.
MRI sequences
Indications
Conventional MRI
  • Basic characterization and local staging of masses especially posterior mediastinal lesions
Diffusion-weighted MRI (Figs. 7A to C)
  • To characterize cellular tumors
  • Pleural deposits and lymph nodal involvement10
Perfusion MRI—time resolved/first pass magnetic resonance angiography (MRA) (Figs. 8A to C)
  • To evaluate pulmonary vasculature, e.g. pulmonary thromboembolism
  • To generate perfusion parameters such as pulmonary blood flow (PBF) and blood volume (PBV)
Cine MRI
  • Useful to evaluate chest wall, diaphragmatic or mediastinal invasion
Cardiac MRI (double inversion recovery sequences, cine MRI)
  • For cardiac invasion
zoom view
Figs. 7A to C: MRI with DWI (A to C) showing a large neurofibroma in the mediastinum (thin arrow) along with multiple tiny neurofibromas throughout the chest in a patient with neurofibromatosis.
With the advances in the imaging technology the morphologic imaging has been complimented by functional information which can be obtained from newer techniques. These functional information can be used to characterize the lesion, even predict the histopathology, prognosticate or to assess response to treatment. The various types of functional information obtained from advanced imaging modalities are listed below.
Table 7   Functional imaging techniques.
Imaging technique
Functional information
Perfusion CT
  • Provides information on the perfusion characteristics such as blood flow, blood volume, etc.
  • Can guide the biopsy to avoid necrosis and maximize the yield
  • Response evaluation after therapy
Dual energy CT
  • Characterize the tissue
  • Iodine map to better evaluate tissue enhancement
  • Can be used to evaluate lung perfusion
Apparent diffusion coefficient (ADC) in diffusion-weighted imaging (DWI)
  • Used to quantify the diffusion of water molecules
  • Characterize tumors, detection of metastasis
  • Response evaluation
Perfusion MRI
  • Evaluate pulmonary vasculature
  • Quantification of perfusion parameters
11
zoom view
Figs. 8A to C: Perfusion MRI showing a mass lesion in the right paracardiac region which was isointense on T1-weighted sequence (arrow) (A), hypointense on T2-weighted sequence (B). The periphery of the tumor is solid with increased perfusion whereas the center of the tumor is showing less perfusion (C). Regions of interest (ROIs) are placed over the periphery and center of the tumor which generated the perfusion curve and semiquantitative parameters (C).
 
CONCLUSION
Computed tomography and positron emission tomography-CT are the most commonly used imaging modalities used to evaluate and stage chest tumors. However, USG and MRI have their own advantages in selected clinical settings especially in children where radiation dose is a major concern.